Poxel (PP:POXEL) is a French pharmaceutical company that recently received $30.1 million in post-IPO equity in 2016. The company has developed an orally active medication called Imeglimin, which targets all three organs and body systems that are affected by diabetes simultaneously: the pancreas, liver, and muscles. The drug is currently undergoing phase 3 clinical work in Japan, and will commence phase 3 trials in the European Union and the United States that will be completed by 2019. The company is also concurrently working on several other pharmaceutical agents in various stages of the development pipeline.
Though the Oxford English Dictionary traces wellness (meaning the opposite of illness) to the 1650s, the story of the wellness movement really begins in the 1950s. New approaches to healthful living were emerging then, inspired in part by the preamble to the World Health Organization’s 1948 constitution: “Health is a state of complete physical, mental and social well-being and not merely the absence of disease or infirmity.” Halbert L. Dunn, chief of the National Office of Vital Statistics, was looking for new terminology to convey the positive aspects of health that people could achieve, beyond simply avoiding sickness. In a series of papers and lectures in the late ’50s, Dunn sketched out his concept of “high-level wellness,” defined as “an integrated method of functioning, which is oriented toward maximizing the potential of which the individual is capable.”
Christina Kalberg is the Executive Director of the Diabetes Research Connection (DRC). She comes to DRC with over 10 years of experience as a senior-level executive effectively integrating passion and in-depth skill into well-crafted marketing, public relations, communications, operations and fundraising campaigns to directly fuel multi-million-dollar revenue growth. Christina is a strategist, deftly aligning staff and other stakeholders. She has a Bachelor’s degree in Journalism with an emphasis in Public Relations and a Master’s degree in Business Administration. Christina is also an adjunct professor for the marketing program at Point Loma Nazarene University, where she teaches Digital and Social Media Marketing.
McInnes, N., Smith, A., Otto, R., Vandermey, J., Punthakee, Z., Sherifali, D., … Gerstein, H. C. (2017, March 15). Piloting a remission strategy in type 2 diabetes: Results of a randomized controlled trial. The Journal of Clinical Endocrinology and Metabolism, 2016-3373. Retrieved from https://academic.oup.com/jcem/article-abstract/doi/10.1210/jc.2016-3373/3070517/Piloting-a-Remission-Strategy-in-Type-2-Diabetes?redirectedFrom=fulltext
What is peripheral neuropathy? Peripheral neuropathy is common among people with diabetes, causing loss of sensitivity in the hands and feet, and in organs such as the kidneys, heart, and eyes. Find out here about other medical conditions and causes that can lead to peripheral neuropathy and result in nerve tingling and muscle wastage or paralysis. Read now
In order to reverse diabetes naturally, remove foods like refined sugar, grains, conventional cow’s milk, alcohol, GMO foods and hydrogenated oils from your diet; incorporate healthy foods like foods high in fiber, chromium, magnesium, healthy fats and clean protein, along with foods with low glycemic loads; take supplements for diabetes; follow my diabetic eating plan; and exercise to balance blood sugar.
Rarely, people with diabetes erupt in blisters. Diabetic blisters can occur on the backs of fingers, hands, toes, feet and sometimes on legs or forearms. These sores look like burn blisters and often occur in people who have diabetic neuropathy. They are sometimes large, but they are painless and have no redness around them. They heal by themselves, usually without scars, in about three weeks. The only treatment is to bring blood sugar levels under control.
At Diabetes Daily, we prefer using the word remission over cure because far too often the state of diabetes returns even with people’s best efforts. Regardless of the definition of a cure, finding a way to live with little to know highs or lows is a worthwhile endeavor. Long-term studies show that even a few years of great blood sugars significantly reduces your long-term risk of complications.
Access the ADA’s health and wellness programs as part of your ADA student membership. Each state association has a health and wellness director who can help you with anything from stress, mental well-being and addiction. You can contact your state association directly or call ADA Manager of Dentist Health and Wellness Alison Bramhall at 312-440-2622.
The first WHO Global report on diabetes demonstrates that the number of adults living with diabetes has almost quadrupled since 1980 to 422 million adults. Factors driving this dramatic rise, which is largely on account of type 2 diabetes, include overweight and obesity. The new report calls upon governments to ensure that people are able to make healthy choices and that health systems are able to diagnose, treat and care for people with diabetes.
“Diabetes type 1 is very different from your standard disease. Insulin requirements vary greatly from one day to another and there is no way patients can know what they need,” Roman Hovorka, Professor at the University of Cambridge, explained to me during an interview. His research group is working on the development of an algorithm that can accurately predict insulin requirements for a specific patient at any moment.
Exercise naturally supports your metabolism by burning fat and building lean muscle. To prevent and reverse diabetes, make exercise a part of your daily routine. This doesn’t necessary mean that you have to spend time at the gym. Simple forms of physical activity, like getting outside and walking for 20 to 30 minute every day, can be extremely beneficial, especially after meals. Practicing yoga or stretching at home or in a studio is another great option.
Since cardiovascular disease is a serious complication associated with diabetes, some have recommended blood pressure levels below 130/80 mmHg. However, evidence supports less than or equal to somewhere between 140/90 mmHg to 160/100 mmHg; the only additional benefit found for blood pressure targets beneath this range was an isolated decrease in stroke risk, and this was accompanied by an increased risk of other serious adverse events. A 2016 review found potential harm to treating lower than 140 mmHg. Among medications that lower blood pressure, angiotensin converting enzyme inhibitors (ACEIs) improve outcomes in those with DM while the similar medications angiotensin receptor blockers (ARBs) do not. Aspirin is also recommended for people with cardiovascular problems, however routine use of aspirin has not been found to improve outcomes in uncomplicated diabetes.
A representative for the Centers for Medicare and Medicaid Services, however, told Gizmodo the agency “has not received a reconsideration request” to overhaul its coverage of bariatric surgery as of yet. Gizmodo also asked several of the leading insurance companies, such as Anthem, Aetna, and UnitedHealthcare, about any possible revision in their coverage policies. Only Aetna replied, stating it constantly evaluates “new published peer-reviewed studies and medical research when developing our clinical policies.” But the company seemingly has no current plans to roll out any changes.
That call went unheeded, however, as preventative has managed to survive as a variant, albeit a much less popular one. A search on the Corpus of Contemporary American English finds preventive beating preventative by a ratio of about 6 to 1 in current written usage, across both academic and nonacademic texts. You can still get away with using preventative in standard English, but that extraneous syllable won't gain you anything, other than disdain from the sticklers.
Dr. Shiel received a Bachelor of Science degree with honors from the University of Notre Dame. There he was involved in research in radiation biology and received the Huisking Scholarship. After graduating from St. Louis University School of Medicine, he completed his Internal Medicine residency and Rheumatology fellowship at the University of California, Irvine. He is board-certified in Internal Medicine and Rheumatology.
The word mellitus (/məˈlaɪtəs/ or /ˈmɛlɪtəs/) comes from the classical Latin word mellītus, meaning "mellite" (i.e. sweetened with honey; honey-sweet). The Latin word comes from mell-, which comes from mel, meaning "honey"; sweetness; pleasant thing, and the suffix -ītus, whose meaning is the same as that of the English suffix "-ite". It was Thomas Willis who in 1675 added "mellitus" to the word "diabetes" as a designation for the disease, when he noticed the urine of a diabetic had a sweet taste (glycosuria). This sweet taste had been noticed in urine by the ancient Greeks, Chinese, Egyptians, Indians, and Persians.
Cinnamon contains a bioactive compound that can help to fight and prevent diabetes. Cinnamon is known to stimulate the insulin activity and thus regulate the blood sugar level. As excess of anything is bad, likewise cinnamon if taken in excess can increase the risk of liver damage due to a compound called coumarin present in it. The true cinnamon, not the one buy from shops (Cassia cinnamon) is safer to have.
"Yes, it's a frustrating case," Darkes told Live Science in an email. "But the doctors have to be as accurate as they can be with what's happened, so they've given a 2-year time scale for completed type 1 reversal." Darkes explained that if he can go without insulin injections for two years, his doctors will be 100 percent sure his diabetes is gone.
Founded in 2007, San Francisco startup NGM Biopharmaceuticals is a pharmaceutical company that has raised $295.4 million, with pharmaceutical giant Merck & Co., as one of its most recent investors. The company has just filed to sell $75 million of its common stock in an IPO. The company’s primary candidate for treating diabetes is NGM313, an engineered antibody that binds to a novel pathway that reduces insulin resistance. After the successful conclusion of a phase I on the drug, NGM plans to license the antibody to Merck.
Metformin is generally recommended as a first line treatment for type 2 diabetes, as there is good evidence that it decreases mortality. It works by decreasing the liver's production of glucose. Several other groups of drugs, mostly given by mouth, may also decrease blood sugar in type II DM. These include agents that increase insulin release, agents that decrease absorption of sugar from the intestines, and agents that make the body more sensitive to insulin. When insulin is used in type 2 diabetes, a long-acting formulation is usually added initially, while continuing oral medications. Doses of insulin are then increased to effect.
Dr. Nyitray established Encellin soon after she received her PhD in chemistry and chemical biology from the University of California San Francisco in 2015. Her work at UCSF, with advisor Tejal Desai, PhD, chair of the Department of Bioengineering and Therapeutic Sciences in UCSF’s schools of Pharmacy and Medicine, focused on developing a packaging system for islet cells.
"Advocacy Month was appropriately themed “Midterms Matter: Add your voice,” in light of the Nov. 6 election. ASDA members across the country made sure their fellow students went to the polls to represent the dental profession. It was an especially exciting election season since five dentists were elected to Congress." Read more on ASDA's blog, Mouthing Off
Anti-seizure drugs. Some medications used to treat seizure disorders (epilepsy) are also used to ease nerve pain. The American Diabetes Association recommends starting with pregabalin (Lyrica). Others that have been used to treat neuropathy are gabapentin (Gralise, Neurontin) and carbamazepine (Carbatrol, Tegretol). Side effects may include drowsiness, dizziness and swelling.
I bring this up because sleep apnea increases a person’s risk for developing type 2 diabetes. Also, sleep-disordered breathing is also related to proper nutrition throughout life. And perhaps most importantly, the first line of defense in catching sleep-disordered breathing in patients early, are dentists. This is another area where dentists must get involved if we want to tackle the issue of pervasive type 2 diabetes with any success.
Today, 425 million adults live with diabetes, and that number is expected to grow to 629 million by 2045, with the greatest number between the ages of 40 to 59 years old. The global prevalence of diabetes has risen from 4.7 percent in 1980 to 8.5 percent in 2014, with the proportion of type 2 diabetes increasing around the world. On top of those numbers, another whopping 352 million people are at risk of developing type 2 diabetes. According to the 2017 Economic Cost of Diabetes survey sponsored by the American Diabetes Association, the total cost of diabetes was estimated to be $327 billion, a 26 percent increase since 2012. About three-quarters of those costs are associated with direct medical expenditures. Patients with diabetes are expected to pay an average of $9,600 in additional medical costs annually. A diabetes cure could cut out a nice chunk of fat out of those costs, potentially worth $245 billion from the 30 million diabetic Americans alone.
The body obtains glucose from three main sources: the intestinal absorption of food; the breakdown of glycogen (glycogenolysis), the storage form of glucose found in the liver; and gluconeogenesis, the generation of glucose from non-carbohydrate substrates in the body. Insulin plays a critical role in balancing glucose levels in the body. Insulin can inhibit the breakdown of glycogen or the process of gluconeogenesis, it can stimulate the transport of glucose into fat and muscle cells, and it can stimulate the storage of glucose in the form of glycogen.
Maryland company Orgenesis (ORGS) is developing a proprietary therapeutic platform that transforms adult liver cells into insulin-generating cells to provide patients with independent insulin production. Earlier this year, Orgenesis entered into a partnership with HekaBio K.K. to conduct clinical trials in Japan. The company appears to be moving into licensing the technology to other companies for further development.
The earliest surviving work with a detailed reference to diabetes is that of Aretaeus of Cappadocia (2nd or early 3rd century CE). He described the symptoms and the course of the disease, which he attributed to the moisture and coldness, reflecting the beliefs of the "Pneumatic School". He hypothesized a correlation of diabetes with other diseases, and he discussed differential diagnosis from the snakebite which also provokes excessive thirst. His work remained unknown in the West until 1552, when the first Latin edition was published in Venice.